Acorah Software Products - Accounts Production 16.4.675 false true true 31 December 2023 1 January 2023 false 1 January 2024 31 December 2024 31 December 2024 13090844 Mrs M Cherednyk Mr Kostyantyn Puchyn true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13090844 2023-12-31 13090844 2024-12-31 13090844 2024-01-01 2024-12-31 13090844 frs-core:CurrentFinancialInstruments 2024-12-31 13090844 frs-core:Non-currentFinancialInstruments 2024-12-31 13090844 frs-core:CopyrightsPatentsTrademarksServiceOperatingRights 2024-12-31 13090844 frs-core:CopyrightsPatentsTrademarksServiceOperatingRights 2024-01-01 2024-12-31 13090844 frs-core:CopyrightsPatentsTrademarksServiceOperatingRights 2023-12-31 13090844 frs-core:ShareCapital 2024-12-31 13090844 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 13090844 frs-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13090844 frs-bus:FilletedAccounts 2024-01-01 2024-12-31 13090844 frs-bus:SmallEntities 2024-01-01 2024-12-31 13090844 frs-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 13090844 frs-bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13090844 frs-bus:OrdinaryShareClass1 2024-01-01 2024-12-31 13090844 frs-bus:OrdinaryShareClass1 2024-12-31 13090844 frs-bus:OrdinaryShareClass2 2024-01-01 2024-12-31 13090844 frs-bus:OrdinaryShareClass2 2024-12-31 13090844 frs-bus:OrdinaryShareClass3 2024-01-01 2024-12-31 13090844 frs-bus:OrdinaryShareClass3 2024-12-31 13090844 frs-bus:OrdinaryShareClass4 2024-01-01 2024-12-31 13090844 frs-bus:OrdinaryShareClass4 2024-12-31 13090844 frs-bus:OrdinaryShareClass5 2024-01-01 2024-12-31 13090844 frs-bus:OrdinaryShareClass5 2024-12-31 13090844 1 2024-01-01 2024-12-31 13090844 frs-core:UnlistedNon-exchangeTraded 2024-12-31 13090844 frs-core:UnlistedNon-exchangeTraded 2023-12-31 13090844 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2023-12-31 13090844 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 13090844 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-12-31 13090844 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2023-12-31 13090844 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 13090844 frs-bus:Director1 2024-01-01 2024-12-31 13090844 frs-countries:EnglandWales 2024-01-01 2024-12-31 13090844 2022-12-31 13090844 2023-12-31 13090844 2023-01-01 2023-12-31 13090844 frs-core:CurrentFinancialInstruments 2023-12-31 13090844 frs-core:Non-currentFinancialInstruments 2023-12-31 13090844 frs-core:ShareCapital 2023-12-31 13090844 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31 13090844 frs-bus:OrdinaryShareClass1 2023-01-01 2023-12-31 13090844 frs-bus:OrdinaryShareClass2 2023-01-01 2023-12-31 13090844 frs-bus:OrdinaryShareClass3 2023-01-01 2023-12-31 13090844 frs-bus:OrdinaryShareClass4 2023-01-01 2023-12-31 13090844 frs-bus:OrdinaryShareClass5 2023-01-01 2023-12-31
Registered number: 13090844
Kp Management Corporation Ltd
Unaudited Financial Statements
For The Year Ended 31 December 2024
Pro-Capital Finance
Contents
Page
Statement of Financial Position 1—2
Notes to the Financial Statements 3—7
Page 1
Statement of Financial Position
Registered number: 13090844
2024 2023
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 299,678 -
Investments 5 7,530,567 1,360,222
7,830,245 1,360,222
CURRENT ASSETS
Receivables 6 100 100
Investments 7 211,366 -
Cash at bank and in hand 36,812 606,011
248,278 606,111
Payables: Amounts Falling Due Within One Year 8 (1,653,928 ) (30,556 )
NET CURRENT ASSETS (LIABILITIES) (1,405,650 ) 575,555
TOTAL ASSETS LESS CURRENT LIABILITIES 6,424,595 1,935,777
Payables: Amounts Falling Due After More Than One Year 9 - (1,957,500 )
NET ASSETS/(LIABILITIES) 6,424,595 (21,723 )
CAPITAL AND RESERVES
Called up share capital 10 6,468,123 100
Income Statement (43,528 ) (21,823 )
SHAREHOLDERS' FUNDS 6,424,595 (21,723)
Page 1
Page 2
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Income Statement.
On behalf of the board
Mrs M Cherednyk
Director
24/07/2025
The notes on pages 3 to 7 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Kp Management Corporation Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13090844 . The registered office is 12 Mulberry Place, Pinnell Road, London, SE9 6AR.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. 
The functional currency of the company is considered to be pound sterling (£) because that is the currency of the primary economic environment in which the company operates. The financial statements are presented in pound sterling (£).
2.2. Going Concern Disclosure
The director has considered the company's financial position, liquidity and future performance together with financial projections for the company over the foreseeable future. After making enquiries, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, she continues to adopt the going concern basis in preparing the annual financial statements.
2.3. Intangible Fixed Assets and Amortisation - Intellectual Property
Intellectual property assets are initially recognised at cost, which includes the purchase price and any directly attributable costs. Amortisation begins when the assets are available for use and is calculated on a straight-line basis over their estimated useful lives. If the assets are not yet in use, no amortisation is charged. The useful life is determined based on the period over which the assets are expected to generate economic benefits and is reviewed annually. Intellectual property assets are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable, with an impairment loss recognised if the carrying amount exceeds the recoverable amount.
2.4. Financial Instruments
The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.
2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the financial position date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.6. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
Page 3
Page 4
2.7. Investments
Unlisted investments are stated at historical cost less provision for any diminution in value.
Short-term investments are initially measured at cost, which includes transaction costs. Subsequently, they are measured at fair value with changes in fair value recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment. Short-term investments are classified as current assets if they are expected to be realised within 12 months after the reporting date
2.8. Receivables
Receivables are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables.
2.9. Payables
Payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method. 
2.9.  Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
3. Average Number of Employees
Average number of employees during the year was: NIL (2023: NIL)
- -
4. Intangible Assets
Intellectual Property
£
Cost
As at 1 January 2024 -
Additions 299,678
As at 31 December 2024 299,678
Net Book Value
As at 31 December 2024 299,678
As at 1 January 2024 -
Intellectual property assets represent the company's acquired rights to computer programs, industrial designs, and utility models. As of the reporting date, these assets are not yet in use and therefore no amortisation has been charged. The expected date for these assets to be available for use is currently unknown. Amortisation will commence once the assets are available for use.
Page 4
Page 5
5. Investments
Unlisted
£
Cost
As at 1 January 2024 1,360,222
Additions 6,170,345
As at 31 December 2024 7,530,567
Provision
As at 1 January 2024 -
As at 31 December 2024 -
Net Book Value
As at 31 December 2024 7,530,567
As at 1 January 2024 1,360,222
Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:
The company holds 50% of ordinary voting rights and shares of LLC "Kram Invest", a company incorporated in Ukraine. The principal activity of LLC "Kram Invest" is that of General medical practice. The loss for the financial year ending 31/12/2024 of LLC "Kram Invest" was £208,010 and the aggregate amount of capital and reserves at the end of the year was -£1,130,882. 
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzky likiv", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyzky likiv" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyzky likiv" was £263,273 and the aggregate amount of capital and reserves at the end of the year was £441,672. 
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyskykh tsin Kharkiv", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyskykh tsin Kharkiv" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyskykh tsin Kharkiv" was £346,380 and the aggregate amount of capital and reserves at the end of the year was £705,792. 
The company holds 60% of ordinary voting rights and shares of LLC "Dariyafarma", a company incorporated in Ukraine. The principal activity of LLC "Dariyafarma" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Dariyafarma" was £271,265 and the aggregate amount of capital and reserves at the end of the year was £354,630. 
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzkykh tsin TM", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyzkykh tsin TM " is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyzkykh tsin TM " was £257,138 and the aggregate amount of capital and reserves at the end of the year was £557,520. 
The company holds 60% of ordinary voting rights and shares of LLC "Dniprofarma", a company incorporated in Ukraine. The principal activity of LLC "Dniprofarma" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Dniprofarma" was £438,652 and the aggregate amount of capital and reserves at the end of the year was £1,020,586. 
The company holds 60% of ordinary voting rights and shares of LLC "Apteka Shar@", a company incorporated in Ukraine. The principal activity of LLC "Apteka Shar@" is that of Retail trade of pharmaceutical goods in specialised stores. The loss for the financial year ending 31/12/2024 of LLC "Apteka Shar@" was £6,835 and the aggregate amount of capital and reserves at the end of the year was -£21,373.
The company holds 60% of ordinary voting rights and shares of LLC "Yniiafarm", a company incorporated in Ukraine. The principal activity of LLC "Yniiafarm" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Yniiafarm" was £260,772 and the aggregate amount of capital and reserves at the end of the year was £649,554.
The company holds 60% of ordinary voting rights and shares of LLC "Transfarm-Dnipro", a company incorporated in Ukraine. The principal activity of LLC "Transfarm-Dnipro" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Transfarm-Dnipro" was £341,983 and the aggregate amount of capital and reserves at the end of the year was £659,422.
...CONTINUED
Page 5
Page 6
5. Investments - continued
The company holds 60% of ordinary voting rights and shares of LLC "Apteka Nyzkykh Tsin Kremin", a company incorporated in Ukraine. The principal activity of LLC "Apteka Nyzkykh Tsin Kremin" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka Nyzkykh Tsin Kremin" was £401,720 and the aggregate amount of capital and reserves at the end of the year was £1,420,938.
The company holds 60% of ordinary voting rights and shares of LLC "Apteka-Magnoliya", a company incorporated in Ukraine. The principal activity of LLC "Apteka-Magnoliyan" is that of Retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka-Magnoliya" was £223,996 and the aggregate amount of capital and reserves at the end of the year was £398,694.
The company holds 100% of ordinary voting rights and shares of LLC "Avers", a company incorporated in Ukraine. The principal activity of LLC "Avers" is that of Leasing and exploitation of own or leased real estate. The loss for the financial year ending 31/12/2024 of LLC "Avers" was £85,247 and the aggregate amount of capital and reserves at the end of the year was -£197,080.
The company holds 100% of ordinary voting rights and shares of LLC "Extra Group of Companies", a company incorporated in Ukraine. The principal activity of LLC "Extra Group of Companies" is that of Buying and selling of own real estate property. The loss for the financial year ending 31/12/2024 of LLC "Extra Group of Companies" was £16,498 and the aggregate amount of capital and reserves at the end of the year was -£55,866.
The company holds 33.3% of ordinary voting rights and shares of LLC "AlliaPharm Europe", a company incorporated in Hungary. The principal activity of LLC "AlliaPharm Europe " is that of pharmaceutical manufacturing. The loss for the financial year ending 31/12/2024 of LLC "AlliaPharm Europe" was £4,799 and the aggregate amount of capital and reserves at the end of the year was -£11,607.
6. Receivables
2024 2023
£ £
Due within one year
Called up share capital not paid 100 100
7. Current Asset Investments
2024 2023
£ £
Unlisted investments 211,366 -
The current asset investment represents an investment in fixed-interest securities with an interest rate of 2.5% and a maturity date of 13th June 2025.
8. Payables: Amounts Falling Due Within One Year
2024 2023
£ £
Other loans 1,618,180 -
Other creditors 2,130 1,018
Accruals and deferred income 4,080 4,338
Director's loan account 29,538 25,200
1,653,928 30,556
9. Payables: Amounts Falling Due After More Than One Year
2024 2023
£ £
Other loans - 1,957,500
Page 6
Page 7
10. Share Capital
2024 2023
Allotted, called up but not fully paid £ £
100 Ordinary Shares of £ 1.00 each 100 100
6,168,345 Series A shares of £ 1.00 each 6,168,345 -
92,138 Series B shares of £ 1.00 each 92,138 -
16,674 Series C shares of £ 1.00 each 16,674 -
190,866 Series D shares of £ 1.00 each 190,866 -
6,468,123 -
11. Reserves
The retained earnings reserve represents cumulative profit or losses net of dividends paid and other adjustments.
12. Post Balance Sheet Events
There have been no significant events between the year end and the date of approval of these accounts which would require a change to, or disclosure in, the financial statements.
13. Related Party Transactions
At the balance sheet date a balance of £1,618,180 (2023: £1,957,500) was due to a shareholder of the company, K. Puchyn under non-interest bearing loan.
14. Ultimate Controlling Party
The company's ultimate controlling party is Mr Kostyantyn Puchyn by virtue of his ownership of 100% of the issued share capital in the company.
15. Exemption from preparing group accounts
The company and its subsidiaries comprise a small group. The company has therefore taken advantage of the exemption provided in Section 399 of the Companies Act 2006 not to prepare group financial statements and accordingly these financial statements present information about the company as a single undertaking.
Page 7